Summary
The pharmaceutical industry faces enormous challenges — from changes in how pharmaceutical companies develop and source products, to pricing pressures, to increasingly stringent regulatory environments. These business changes are driving IT to both reduce business costs and support new business operating models leveraging Digital Business Networks and Social Computing. As a consequence of these changes at the business and IT level, the heads of enterprise architecture (EA) within pharmas are deeply examining their EA programs and/or their priorities. The most prominent change Forrester recommends to pharmaceutical enterprise architecture programs is to endorse the concept of "next-generation EA."
Log in to continue reading
Client log in
Welcome back. Log in to your account to continue reading this research.
Become a client
Become a client today for these benefits:
- Stay ahead of changing market and customer dynamics with the latest insights.
- Partner with expert analysts to make progress on your top initiatives.
- Get answers from trusted research using Izola, Forrester's genAI tool.
Purchase this report
This report is available for individual purchase ($1495).